Research Update

ReNeuron Group plc
18 October 2007



ReNeuron to present positive pre-clinical data concerning its ReN005 stem cell
line for Huntington's disease


Guildford, UK, 18 October 2007: ReNeuron Group plc (LSE: RENE.L) today announces
that it will be participating in the 3rd World Congress on Regenerative
Medicine, taking place at The Congress Center, Leipzig, Germany on 18-20
October.  The Company will present in the Neurodegeneration and Repair stream on
the morning of 20 October.


Dr Marc-Oliver Baradez of ReNeuron will present pre-clinical efficacy and
characterisation data concerning ReNeuron's ReN005 stem cell line for
Huntington's disease,  indicating its potential as a cell-based therapeutic for
this condition.  A master cell bank for ReN005 has recently been manufactured to
Good Manufacturing Practice (cGMP) standards, as part of the pre-clinical
development programme for this cell line.  This programme is being currently
supported by a grant awarded under the UK Government's Technology Programme,
administered by the Department for Business, Enterprise and Regulatory Reform
(formerly the DTI).


More information about the congress may be found at www.regmed.org.

Enquiries:

ReNeuron
Michael Hunt, Chief Executive Officer            Tel: [phone]
Dr John Sinden, Chief Scientific Officer

Financial Dynamics
Europe
David Yates                                      Tel: [phone]
Lara Mott
US
Robert Stanislaro                                Tel : [phone]





About Huntington's disease

Huntington's disease is an inherited, progressive and fatal neurodegenerative
disorder that affects one in 10,000 people.  The disease is now recognised as
one of the more common genetic disorders.  It typically begins in mid-life,
between the ages of 30 and 45, although onset may occur as early as the age of
two.  Over a period of 10 to 20 years, the disease slowly diminishes the
patient's ability to walk, think, talk and reason, ultimately making the patient
completely dependent upon others for his or her care.  In the US, approximately
30,000 patients suffer from the disease with 200,000 people genetically at risk.
There are currently no effective treatments or cures for the disease.



About ReNeuron

ReNeuron is a leading, UK-based stem cell therapy business.  It is applying its
novel stem cell platform technologies in the development of ground-breaking stem
cell therapies to serve significant and unmet or poorly-met clinical needs.  The
Company operates from laboratories in Surrey, UK and Los Angeles, California,
USA.



ReNeuron has used its c-mycER technology to generate genetically stable neural
stem cell lines.  This technology platform has multi-national patent protection
and is fully regulated by means of a chemically-induced safety switch.  Cell
growth can therefore be completely arrested prior to in vivo implantation.



ReNeuron has filed for approval to commence initial clinical studies in the US
with its lead ReN001 stem cell therapy for chronic stroke disability.  This
represents the world's first such filing concerning a neural stem cell treatment
for a major neurological disorder.  There are an estimated 50 million stroke
survivors worldwide, approximately one half of which are left with permanent
disabilities.  The annual health and social costs of caring for these patients
is estimated to be in excess of £5 billion in the UK and in excess of US$50
billion in the US.



In addition to its stroke programme, ReNeuron is developing stem cell therapies
for Parkinson's disease, Huntington's disease, Type 1 diabetes and diseases of
the retina.  The Company recently announced the acquisition of the business
assets of AmCyte Inc. in the US, bringing clinically-tested cell encapsulation
technology to ReNeuron's ReN002 diabetes programme.



ReNeuron has leveraged its stem cell technologies into non-therapeutic areas -
its ReNcell(R) range of cell lines for use in research and in drug discovery
applications in the pharmaceutical industry.  ReNeuron's ReNcell(R)CX and
ReNcell(R)VM neural cell lines are marketed worldwide under license by Millipore
Corporation.



ReNeuron's shares are traded on the London AIM market under the symbol RENE.L.



Further information on ReNeuron and its products can be found at
www.reneuron.com.



Data sources: Huntington's Disease Society of America; UK Stroke Association;
American Stroke Association.



This announcement contains forward-looking statements with respect to the
financial condition, results of operations and business achievements/performance
of ReNeuron and certain of the plans and objectives of management of ReNeuron
with respect thereto. These statements may generally, but not always, be
identified by the use of words such as 'should', 'expects', 'estimates',
'believes' or similar expressions. This announcement also contains
forward-looking statements attributed to certain third parties relating to their
estimates regarding the growth of markets and demand for products. By their
nature, forward-looking statements involve risk and uncertainty because they
reflect ReNeuron's current expectations and assumptions as to future events and
circumstances that may not prove accurate.  A number of factors could cause
ReNeuron's actual financial condition, results of operations and business
achievements/performance to differ materially from the estimates made or implied
in such forward-looking statements and, accordingly, reliance should not be
placed on such statements


                      This information is provided by RNS
            The company news service from the London Stock Exchange